Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUH1JX)

Drug Name
EMC-0901 Drug Info
Synonyms EMC-0902; Dipeptidyl peptidase IV inhibitors (diabetes), EMC Microcollections; DPP-IV inhibitors (diabetes), EMC Microcollections
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Investigative [1]
Cross-matching ID
TTD Drug ID
DMUH1JX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Saxagliptin DMGXENV Type-2 diabetes 5A11 Approved [2]
Sitagliptin DMGDKXN Cystic fibrosis CA25 Approved [3]
Alogliptin DM8WI3R Type-2 diabetes 5A11 Approved [4]
Linagliptin DMWFJTR Non-insulin dependent diabetes 5A11 Approved [5]
Vildagliptin DMYN59P Type-2 diabetes 5A11 Approved [6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [7]
Anagliptin DMJXIC9 Type-2 diabetes 5A11 Approved [8]
SaxaDapa FDC DMAPRWV Diabetic complication 5A2Y Phase 3 [9]
LC-150444 DM09RKB Type-2 diabetes 5A11 Phase 3 [10]
Dutogliptin DMM5VTA Type-2 diabetes 5A11 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
2 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3 Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
4 Clinical pipeline report, company report or official report of Takeda (2009).
5 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
6 Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
9 Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
10 Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
11 Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.